pembrolizumab vs. chemo in first-line mcrc
Published 3 years ago • 89 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
4:35
keynote-062: pembrolizumab vs. chemo in 1l advanced gastric cancer
-
2:56
keynote-177: final pfs analysis of pembrolizumab in patients with msi-h/dmmr mcrc
-
5:20
pembrolizumab improves on chemo in msi-h/dmmr mcrc
-
4:32
first-line regorafenib 80mg/day with pembrolizumab in advanced hcc
-
4:56
asco: pembrolizumab vs. chemotherapy for msi-h metastatic colorectal cancer
-
1:08
first-line durvalumab monalizumab in microsatellite-stable crc
-
4:25
fire-4.5: folfoxiri plus either bevacizumab or cetuximab in mcrc
-
3:57
pembrolizumab plus 5-fu and cisplatin for first-line treatment in...
-
6:57
keynote-177 discussion: chemo-immunotherapy, pseudoprogression & biomarkers
-
3:35
adding chemotherapy to immunotherapy in metastatic crc
-
5:30
ctdna monitoring to assess clinical outcomes in mcrc treated with front-line chemotherapy
-
1:24
fire-4.5: folfoxiri plus either bevacizumab or cetuximab as 1l treatment of braf v600e-mutant mcrc
-
2:29
overcoming resistance to immunotherapy as first-line therapy in gastric cancer
-
7:29
first-line treatment recommendations based on tmb
-
2:42
paradigm: panitumumab versus bevacizumab in ras-wt mcrc
-
3:01
deeper: m-folfoxiri and cetuximab versus bevacizumab in mcrc
-
2:45
1l folfoxiri plus cetuximab or bevacizumab for ras wild-type mcrc
-
2:03
antibiotics impact outcomes with pembrolizumab in nsclc patients
-
13:18
debate 1: first-line treatment of metastatic colorectal cancer - calgb 80405